Full-text resources of CEJSH and other databases are now available in the new Library of Science.
Visit https://bibliotekanauki.pl

Results found: 4

first rewind previous Page / 1 next fast forward last

Search results

Search:
in the keywords:  right to health
help Sort By:

help Limit search:
first rewind previous Page / 1 next fast forward last
EN
The aim of the article is to offer proposals for reforming and speeding up health care in Ukraine, in particular by comparing the current system with a decentralized system. The methodology of this research follows basic social science methods (formal analysis, inductive method, deductive method, analogy, synthesis, etc.). With these methods, we address the issues of the health care reform in Ukraine. The article explores the issue of improving the health care in Ukraine. The Ukrainian government is carrying out two important reforms – a health care reform and a decentralization reform that includes changes in the municipal government. These two reforms have a huge potential for improving Ukraine’s health care system. Such potential remains largely untapped.
EN
One of the major components of the right to health is the access to health care services. The study focuses on the interpretation of article 68 paragraph 2 of the Constitution, paying particular attention to the current jurisprudence of the Supreme Court and the Constitutional Tribunal in this field. In particular, the study raises issues of the obligation to finance health care benefits from public funds. The interpretation of article 68 primarily leads to the conclusion that the legislature should aim at fully financing health care benefits from the public funds. The Constitution stipulates that the State, by guarantying everyone the right to health, takes on the burden of ensuring citizens' access to health care services to the fullest possible extent. The obligation to determine the conditions and scope of benefits includes the realization of this purpose. Financial difficulties related to the organization of the effective access to health care services can not become a mean of interpreting the Constitution.
EN
The monopoly enjoyed by pharmaceutical manufacturers, resulting from the protection of intellectual property, directly affects the price of medicinal products and thus their availability, especially in developing and least-developed countries. The aim of the article was to examine the provisions of the Agreement on Trade-Related Aspects of Intellectual Property Rights adopted under the World Trade Organization, an attempt to answer the question of whether it is possible to reconcile the protection of intellectual property with the human right to health.
PL
Monopol przysługujący producentom leków, wynikający z ochrony własności intelektualnej, wpływa bezpośrednio na cenę produktów leczniczych, a co za tym idzie na ich dostępność, szczególnie w krajach rozwijających się i najmniej rozwiniętych. Celem artykułu była analiza postanowień porozumienia w sprawie handlowych aspektów praw własności intelektualnej, przyjętego w ramach Światowej Organizacji Handlu, a także próba odpowiedzi na pytanie, czy możliwe jest pogodzenie ochrony własności intelektualnej z prawem człowieka do zdrowia.
EN
Using the example of a global pharmaceutical industry, I examine the role of private companies in fulfilling social aims. I address the problem of aid in the context of availability of affordable and safe medicines in developing countries, which is one aspect of fulfilling the right to health. Are the mechanisms of free market and philanthropic actions of pharmaceutical companies sufficient to guarantee essential medicines to the most vulnerable inhabitants of the world? Are international pharmaceutical concerns obliged to guarantee human rights only or to deliver human rights, in particular the right to health, as well? The article presents the conflict of interests between profit-driven pharmaceutical industry and ethically-driven public health, which can be fully addressed only by certain legal regulations. The thesis argued in the article is that free market itself cannot solve its failures (such as undersupply of innovations, undersupply of non-beneficial medicines, monopolistic policies and pricing); to solve the problem it is required to set up public institutions and legal regulations of both local and global scope. Neither free market, nor benevolent aid actions of pharmaceutical companies can address the problem of health care in developing countries, where the lack of medicines is a small aspect of a much broader and intricate problem of poverty and the weakness of state institutions which are not responsive to the basic needs of its citizens.
first rewind previous Page / 1 next fast forward last
JavaScript is turned off in your web browser. Turn it on to take full advantage of this site, then refresh the page.